Concepedia

Sergey Ryazanov

SR

Statistics

Publications

23

Citations

1.6K

H-Index

19

Active since

2013

Affiliations

Max Planck Institute for Biophysical Chemistry(Current)

Ludwig-Maximilians-Universität München

Nanoscale Microscopy and Molecular Physiology of the Brain Cluster of Excellence 171 — DFG Research Center 103

University of Göttingen

German Center for Neurodegenerative Diseases

Sergey Ryazanov is an author at Max Planck Institute for Biophysical Chemistry specializing in medicine, biochemistry, and natural sciences.

ORCID

Top concepts

Publications per year

2013–2023

23

Publications

23

Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease

Jens A. Wagner, Sergey Ryazanov, Andrei Leonov et al. · Acta Neuropathologica · 2013 · 439 citations · Full text

Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson’s disease model

Michał Węgrzynowicz, Dana Bar-On, Laura Calò et al. · Acta Neuropathologica · 2019 · 125 citations · Full text

Anle138b modulates α‐synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy

Antonio Heras‐Garvin, Daniel Weckbecker, Sergey Ryazanov et al. · Movement Disorders · 2018 · 105 citations · Full text

Cardiolipin Promotes Pore-Forming Activity of Alpha-Synuclein Oligomers in Mitochondrial Membranes

Stephanie Ghio, Angelique Camilleri, Mario Caruana et al. · ACS Chemical Neuroscience · 2019 · 101 citations

[11C]MODAG-001—towards a PET tracer targeting α-synuclein aggregates

Laura Kuebler, Sabrina Buss, Andrei Leonov et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2020 · 89 citations · Full text

Rows per page

1–5 of 23